Results 111 to 120 of about 820 (140)
Some of the next articles are maybe not open access.
The role of emicizumab in acquired hemophilia A
Hematology, 2023Abstract Acquired hemophilia is a rare bleeding disorder that predominantly affects older people with potential underlying comorbidities, including cardiovascular and thrombotic risk factors. The current standard therapies with hemostatic agents for acute bleeding and immunosuppression often require inpatient management, are not approved
Jacqueline, Poston +1 more
openaire +2 more sources
Emicizumab for the treatment of acquired hemophilia A
Blood, 2021Abstract Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents and human or porcine FVIII are currently standard of care.
Paul Knoebl +5 more
openaire +2 more sources
Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement
Pathology, 2022Emicizumab is a recombinant, humanised bispecific antibody which acts as a FVIII mimetic and is a therapeutic option for haemophilia A. Plasma emicizumab levels may sometimes be required. Multiple one-stage clotting assays (OSA) and one human component chromogenic assay (CSA) were used to measure emicizumab both centrally and by a field study.
Geoffrey Kershaw +4 more
openaire +2 more sources
Emicizumab for hemophilia A without inhibitors
Expert Review of Hematology, 2019Introduction: Hemophilia A (HA) is an inherited bleeding disorder that, if not properly treated, is associated with debilitating joint damage due to recurrent hemarthroses as well as life-threatening bleeds including intracranial hemorrhage. For decades, the only method to prevent bleeding events was to infuse factor (F) VIII concentrates intravenously
Lorraine Cafuir +3 more
openaire +2 more sources
Emicizumab in Children with Severe Hemophilia A
Indian Journal of PediatricsTo assess the effectiveness and tolerability of emicizumab prophylaxis in hemophilia A (HA). Emicizumab is a novel therapeutic drug which is the first and only non-factor replacement agent licensed for use in people with HA.Pediatric patients aged 1 mo to 12 y with severe HA and frequent / life threatening bleeding events, with or without coagulation ...
Usha Rani Thota +3 more
openaire +2 more sources
Emicizumab for the prevention of bleeds in hemophilia A
Expert Opinion on Biological Therapy, 2019Introduction: The management of hemophilia A with and without inhibitors is challenging with high treatment burden of prophylactic regimens, musculoskeletal complications, poor treatment compliance, poor venous access and therapies with suboptimal levels.
openaire +2 more sources